Sonoma Pharmaceuticals financials
$1.25−1.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q3 '26 Dec 31 | Q2 '26 Sep 30 | Q1 '26 Jun 30 | Q4 '25 Mar 31 | Q3 '25 Dec 31 | Q2 '25 Sep 30 | Q1 '25 Jun 30 | Q4 '24 Mar 31 | Q3 '24 Dec 31 | Q2 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $5.6M | $4.3M | $5.6M | $4.0M | $3.8M | $3.6M | $3.6M | $3.4M | $3.4M | $3.1M | $2.7M |
| Gross profit | $2.6M | $2.2M | $1.6M | $2.1M | $1.5M | $1.5M | $1.3M | $1.4M | $1.3M | $1.1M | $1.5M | $990.0K |
| Gross margin | 40.2% | 39.2% | 37.9% | 37.8% | 36.5% | 40.7% | 35.6% | 38.0% | 38.5% | 31.7% | 46.5% | 36.3% |
| Operating income | -$40.0K | -$1.3M | -$678.0K | -$337.0K | -$1.1M | $147.0K | -$1.0M | -$850.0K | -$1.2M | -$1.0M | -$923.0K | -$1.3M |
| Net income | -$330.0K | -$581.0K | -$819.0K | -$534.0K | -$1.2M | -$776.0K | -$928.0K | -$610.0K | -$1.1M | -$1.1M | -$866.0K | -$1.5M |
| Net margin | −5.2% | −10.4% | −18.8% | −9.5% | −30.9% | −20.7% | −26.0% | −17.0% | −33.7% | −31.0% | −27.6% | −54.3% |
| Diluted EPS | $-0.09 | $-0.33 | $-0.48 | $-0.32 | $-0.76 | $-0.48 | $-0.63 | $-0.59 | $-1.34 | $-0.70 | $-1.59 | $-5.75 |
| EBITDA | -$8.0K | -$1.3M | -$644.0K | -$301.0K | -$1.1M | $178.0K | -$998.0K | -$815.0K | -$1.1M | -$988.0K | -$878.0K | -$1.3M |
| Operating cash flow | -$649.0K | -$519.0K | -$764.0K | -$635.0K | -$2.0M | -$95.0K | $565.0K | $354.0K | -$912.0K | $152.0K | -$1.1M | -$1.2M |
| Free cash flow | -$651.0K | -$548.0K | -$811.0K | -$645.0K | -$2.1M | -$142.0K | $563.0K | $328.0K | -$917.0K | $134.0K | -$1.1M | -$1.2M |
| Diluted shares | 3.8M | 1.7M | 1.7M | 1.6M | 1.6M | 1.6M | 1.5M | 1.0M | 0.9M | 1.5M | 0.5M | 0.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.3M | $2.4M | $2.6M | $3.0M | $3.6M | $5.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $140.0K | $222.0K | $0.00 | $56.0K | $139.0K | $220.0K |
| Total assets | $18.1M | $14.0M | $13.6M | $13.9M | $14.6M | $13.7M |
| Total liabilities | $11.5M | $10.9M | $10.2M | $10.1M | $10.5M | $9.3M |
| Shareholders' equity | $6.6M | $3.1M | $3.4M | $3.8M | $4.1M | $4.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology